Source:http://linkedlifedata.com/resource/pubmed/id/20592248
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
15
|
| pubmed:dateCreated |
2010-10-15
|
| pubmed:databankReference | |
| pubmed:abstractText |
To define a role for hematopoietic stem cell transplantation (HSCT) in infants with acute lymphoblastic leukemia and rearrangements of the mixed-lineage-leukemia gene (MLL(+)), we compared the outcome of MLL(+) patients from trial Interfant-99 who either received chemotherapy only or HSCT. Of 376 patients with a known MLL status in the trial, 297 (79%) were MLL(+). Among the 277 of 297 MLL(+) patients (93%) in first remission (CR), there appeared to be a significant difference in disease-free survival (adjusted by waiting time to HSCT) between the 37 (13%) who received HSCT and the 240 (87%) who received chemotherapy only (P = .03). However, the advantage was restricted to a subgroup with 2 additional unfavorable prognostic features: age less than 6 months and either poor response to steroids at day 8 or leukocytes more than or equal to 300 g/L. Ninety-seven of 297 MLL(+) patients (33%) had such high-risk criteria, with 87 achieving CR. In this group, HSCT was associated with a 64% reduction in the risk of failure resulting from relapse or death in CR (hazard ratio = 0.36, 95% confidence interval, 0.15-0.86). In the remaining patients, there was no advantage for HSCT over chemotherapy only. In summary, HSCT seems to be a valuable option for a subgroup of infant MLL(+) acute lymphoblastic leukemia carrying further poor prognostic factors. The trial was registered at www.clinicaltrials.gov as #NCT00015873 and at www.controlled-trials.com as #ISRCTN24251487.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:AttarbaschiAndisheA,
pubmed-author:BiondiAndreaA,
pubmed-author:CampbellMyriamM,
pubmed-author:De LorenzoPaolaP,
pubmed-author:De RossiGiulioG,
pubmed-author:FeliceMariaM,
pubmed-author:FersterAlinaA,
pubmed-author:HannIanI,
pubmed-author:Interfant-99 Study Group,
pubmed-author:Janka-SchaubGrittaG,
pubmed-author:LausenBirgitteB,
pubmed-author:LeblancThierryT,
pubmed-author:LiChi KongCK,
pubmed-author:MannGeorgG,
pubmed-author:PetersChristinaC,
pubmed-author:PietersRobR,
pubmed-author:RubnitzJeffreyJ,
pubmed-author:SchrappeMartinM,
pubmed-author:SilvermanLewis BLB,
pubmed-author:StittE SES,
pubmed-author:SuppiahRamR,
pubmed-author:SzczepanskiTomaszT,
pubmed-author:ValsecchiMaria GraziaMG,
pubmed-author:VoraAjayA
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
14
|
| pubmed:volume |
116
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2644-50
|
| pubmed:dateRevised |
2010-12-1
|
| pubmed:meshHeading |
pubmed-meshheading:20592248-Age Factors,
pubmed-meshheading:20592248-Disease-Free Survival,
pubmed-meshheading:20592248-Gene Rearrangement,
pubmed-meshheading:20592248-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:20592248-Humans,
pubmed-meshheading:20592248-Leukocyte Count,
pubmed-meshheading:20592248-Myeloid-Lymphoid Leukemia Protein,
pubmed-meshheading:20592248-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:20592248-Prognosis,
pubmed-meshheading:20592248-Risk Factors,
pubmed-meshheading:20592248-Survival Analysis,
pubmed-meshheading:20592248-Treatment Outcome
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study.
|
| pubmed:affiliation |
Berlin-Frankfurt-Münster Study Group, Austria.
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|